A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes

NCT02148861 PHASE1 COMPLETED

This trial is conducted in Europe. The aim of the trial is to investigate the safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of subcutaneously administered NNC0148-0287 (insulin 287) in subjects with type 2 diabetes

Details

Lead sponsor	Novo Nordisk A/S
Phase	PHASE1
Status	COMPLETED
Enrolment	49
Start date	Mon May 26 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Jun 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Diabetes
• Type 2 Diabetes Mellitus

Interventions

• Insulin icodec
• insulin degludec
• placebo

Countries

Germany